Gastric Cancer Clinical Trial
Official title:
Evaluation of the Preventive Effect of Chlorhexidine Acetate Gargle for Upper Gastrointestinal Tract Infection After ESD
Backgrounds: With the continuous improvement of sterilization and endoscopic structure, the
infection caused by endoscopy has gradually declined.With the rapid development of digestive
endoscopic therapy in the past decade, therapeutic endoscopy has been widely carried out
worldwide. These techniques have caused the mucous membrane or deeper damage to achieve the
goal of curing the disease. During therapeutic endoscopic procedures, endogenous bacteria may
be ectopic to the blood circulation due to mucosal or deeper damage. The endoscope is used to
in and out lumens multiple times, and the injections are injected into the tissues through
the accessories. These processes may bring the pathogenic bacteria from the patient's mouth
into the digestive tract through the endoscope and enter the blood through the damaged
mucosa. In addition, bacteremia associated with endoscopic procedures may cause bacterial
infections in distant organs (eg infective endocarditis).
Postoperative infection rates can reach 12-22% . The results of the etiological culture show
that it is consistent with the bacteria of oral bacteria. It is possibly related to multiple
passage into the digestive tract of endoscopic and accessory . However, the endoscopic
operation process will inevitably lead to subsequent infections.
ESD treatment involves endoscopic multiple access to the upper digestive tract through the
mouth, attachments and injection needles and other multiple exposure to the wound, so the
probability of postoperative infection is significantly higher than the average endoscope.
Investigators proposed to gargle patients with chlorhexidine acetate before ESD to improve
the oral microenvironment and reduce the pathogenic bacteria in the oral cavity, so as to
observe whether it can achieve the effect of preventing postoperative infection.
Methods and patients
1. Objectives: This study is a prospective randomized controlled study in single center of
Peking University Third Hospital. The purpose of the study is to evaluate the preventive
effect of chlorhexidine acetate gargle on the infection of early upper gastrointestinal
cancer after endoscopic ESD therapy.
2. Calculation of sample size: According to the postoperative infection rate of 10%, 25%
improvement is given after the gargle is administered, and the error range is calculated
at 2%. The sample size needs 306 cases.
The investigator proposed to gargle patients with chlorhexidine acetate before ESD to improve
the oral microenvironment and reduce the pathogenic bacteria in the oral cavity. The main
purpose of the study is to evaluate the preventive effect of chlorhexidine acetate gargle on
the infection of early upper gastrointestinal cancer after endoscopic ESD therapy.
Patients and Methods:
Patients:
Inclusion criteria:
1. Diagnosis of early gastrointestinal cancer
2. in line with endoscopic ESD treatment indications
3. no limitation of age
Exclusion criteria:
1. patients do not agree with the mouthwash
2. The patient requested surgery
Methods
Screening and enrollment:
1. Patients with early-stage upper gastrointestinal cancer diagnosed endoscopically in the
ivestigator's hospital.
2. ESD indications evaluation: endoscopic ultrasonography was used to assess the depth of
lesion infiltration and surrounding lymph nodes. Abdominal or chest CT was used to
further evaluate local lymph nodes and distant metastases.
3. Patients with indications for treatment sign informed consent
Treatment programs:
1. After the patient signed the informed consent, they will be divided into the
experimental group and control group according to random envelopes in accordance with
the sequence of patients were admitted. Patients in the treatment group are given twice
daily three days before endoscopic treatment.Patients in the controlled group will not
receive gargle.
2. Treatment of second-generation cephalosporins or levofloxacin (allergic cephalosporins)
intravenously half an hour before ESD procedure to prevent infection.
3. The main steps of ESD include: marking around the lesion, submucosal injection to fully
lift of the lesion, cutting the mucosa around the circumference, submucosal peeling to
completely separate the submucosa and the muscularis propria to achieve a complete
resection of the lesion, and checking the wound surface vessels and lesions.
4. Monitor blood routine and body temperature changes on the first and third days after
treatment. If there are signs of infection in the clinic, monitor PCT and add
appropriate antibiotics.
Calculation of sample size: According to the postoperative infection rate of 10%, 25%
improvement is given after the gargle is administered, and the error range is calculated at
2%. The sample size needs 306 cases.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05551416 -
The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
|
||
Completed |
NCT05518929 -
Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients
|
Phase 4 | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03219593 -
Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Recruiting |
NCT05536102 -
The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Active, not recruiting |
NCT04082364 -
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
|
Phase 2/Phase 3 | |
Withdrawn |
NCT03766607 -
Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT01924533 -
Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.
|
Phase 3 | |
Terminated |
NCT01641939 -
A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT04908813 -
Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04249739 -
Pembrolizumab + Capecitabine/Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive
|
Phase 2 | |
Recruiting |
NCT05514158 -
To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)
|
Phase 1 | |
Recruiting |
NCT04931654 -
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 |